近日，美国东田纳西州立大学JamesH. Quillen医学院的Manar Jbara教授团队在CVIA上发表了题目为“应对放射性限制性心肌病的综合策略”《Comprehensive Strategies to Address ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Shares of Edgewise Therapeutics EWTX plunged 47.7% in a week, likely due to safety concerns for its investigational candidate ...

Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Our findings suggest deeper issues are contributing to the increase in the disease, particularly in Black women. Barriers to health care are critical. These include insurance gaps, transportation ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

Feline Hypertrophic Cardiomyopathy (HCM) is the most common heart disease in cats, affecting felines of all breeds and ...